EUVIMEDEUVIMED entdecken
Open Access

Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants

Rahul U Chandrappa iD, Vaishali Satpute Janve, Emily L Days, Jerod S Denton iD

American Journal of Physiology-Cell Physiology · 01.06.2026 · 330 (6) · C1788-C1799

DOI: 10.1152/ajpcell.00239.2026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.06.2026. Verfasst von Rahul U Chandrappa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States. Hauptthemen laut MEDLINE: Shaw Potassium Channels, Gain of Function Mutation, Potassium Channel Blockers, Drug Discovery. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, HHS | National Institutes of Health (NIH), VUMC | Vanderbilt Cancer Center (VICC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study identifies the first structurally diverse collection of small-molecule inhibitors of Kv3.1 potassium channels, highlighting VU426 as a moderately potent, state-dependent inactivator. Notably, VU426 displays enhanced potency against multiple pathogenic gain-of-function Kv3.1 mutants, revealing a mechanism-based strategy for selectively targeting disease-associated channel variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shaw Potassium ChannelsGain of Function MutationPotassium Channel BlockersDrug DiscoveryHumansAnimalsHEK293 CellsXenopus laevisMutationMembrane PotentialsIon Channel Gating

Stichwörter der Autor:innen

HTSKCNC1 mutationsKv3.1automated patch clampgain-of-function

Substanzen

Shaw Potassium ChannelsPotassium Channel BlockersKCNC1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States.
  • Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
  • High Throughput Screening Core Facility, Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee, United States.

ORCID-Profile: Rahul U Chandrappa, Jerod S Denton

Förderung

  • NIMH NIH HHS
  • HHS | National Institutes of Health (NIH)
  • VUMC | Vanderbilt Cancer Center (VICC)
  • HHS | NIH | National Institute of Mental Health (NIMH)

Zitieren

APA

Chandrappa, R. U., Satpute Janve, V., Days, E. L., & Denton, J. S. (2026). Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants. American Journal of Physiology-Cell Physiology, 330(6), C1788-C1799. https://doi.org/10.1152/ajpcell.00239.2026

Vancouver

Chandrappa RU, Satpute Janve V, Days EL, Denton JS. Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants. American Journal of Physiology-Cell Physiology. 2026;330(6):C1788-C1799. doi:10.1152/ajpcell.00239.2026

BibTeX
@article{Chandrappa2026,
  author = {Chandrappa, Rahul U and Satpute Janve, Vaishali and Days, Emily L and Denton, Jerod S},
  title = {Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2026},
  volume = {330},
  number = {6},
  pages = {C1788--C1799},
  doi = {10.1152/ajpcell.00239.2026}
}
Kostenlos starten →